Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07044362 · ClinicalTrials.gov registry record · NA

Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis

A NA study of Colorectal Cancer and Liver Cancer, sponsored by Case Comprehensive Cancer Center.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT07044362: Recruiting NA study of Colorectal Cancer and Liver Cancer, sponsored by Case Comprehensive Cancer Center.

NCT07044362 is a NA study of Colorectal Cancer and Liver Cancer that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 100 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07044362, a NA study of Colorectal Cancer and Liver Cancer, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to learn if histotripsy plus chemotherapy works to treat unresectable, bilobar liver- confined colorectal cancer liver metastasis (CRLM). The main question this clinical trial aims to answer is: • Does the management of this condition with uninterrupted palliative chemotherapy and histotripsy demonstrate improved progression-free survival? Participants will: * Receive chemotherapy treatment per standard procedure. * Undergo histotripsy treatment according to current standard procedures at Cleveland Clinic. * Occasionally receive Computerized Tomography (CT) scan with and without contrast, give biopsy of treated and untreated liver lesions, and participate in a blood draw of up to 3 teaspoons at each in-person visit. * Participate in genetic testing, as a part of the standard of care for the treatment.

Primary Outcome

As assessed by the degree of short-term local tumor control in Colorectal Liver Metastasis(CRLM)

Interventions

  • DRUG Chemotherapy
  • DEVICE HistoSonics Edison® System

Study Locations (1)

Ohio

  • Cleveland Clinic, Case Comprehensive Cancer Center - Cleveland

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-06-30
Est. Completion 2028-10-01
Phase NA
Case Comprehensive Cancer Center

407 total trials

What NCT07044362 shows while recruiting

NCT07044362 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (94% lower).

The record links to 3 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Chemotherapy is the first listed.

NCT07044362 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT07044362 about?

NCT07044362 is a clinical study titled "Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis". The goal of this clinical trial is to learn if histotripsy plus chemotherapy works to treat unresectable, bilobar liver- confined colorectal cancer liver metastasis (CRLM). The main question this clinical trial aims to answer is: • Does the management of this condition with uninterrupted palliative...

What is the current status of trial NCT07044362?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2025-06-30. Estimated completion is 2028-10-01.

What conditions does trial NCT07044362 study?

This clinical trial studies the following conditions: Colorectal Cancer, Liver Cancer, Liver Metastases.

What interventions are being tested in trial NCT07044362?

The interventions under investigation include: Chemotherapy (DRUG), HistoSonics Edison® System (DEVICE).

Who is sponsoring clinical trial NCT07044362?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07044362 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07044362's enrollment target sits among peer trials

100 215th of 381 higher than 162 of 381 other Colorectal Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07044362, the US trial registry maintained by the National Library of Medicine. NCT07044362 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.